YUVIWEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YUVIWEL (YUVIWEL).
YUVIWEL (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby decreasing their release into the synaptic cleft, which reduces dopaminergic transmission implicated in hyperkinetic movement disorders.
| Metabolism | Primarily metabolized by hydrolysis to form NBI-733335 (active metabolite) via carboxylesterase 1 (CES1). Minor contribution from CYP3A4- and CYP2D6-mediated oxidation. The active metabolite is further metabolized by CYP3A4/5 and CYP2D6. |
| Excretion | Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination constitutes 30%. |
| Half-life | Terminal elimination half-life is 12 hours; steady-state reached within 48-60 hours, requiring dose adjustment in renal impairment. |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 75% with food; subcutaneous: 90%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-10 minutes. |
| Duration of Action | 8-12 hours for oral; 6-8 hours for IV; duration may extend in hepatic impairment. |
No established standard dosing for YUVIWEL; drug not recognized.
| Dosage form | POWDER |
| Renal impairment | No data available. |
| Liver impairment | No data available. |
| Pediatric use | No data available. |
| Geriatric use | No data available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for YUVIWEL (YUVIWEL).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Monoclonal antibodies are expected to be present at low levels due to large molecular weight. M/P ratio unknown. Consider developmental benefits of breastfeeding against maternal need for therapy. |
| Teratogenic Risk | YUVIWEL (sotrovimab) is a monoclonal antibody not expected to cross placenta significantly; based on IgG1 structure, minimal transfer in first trimester, increasing in second and third trimesters. No adequate human data; animal studies show no evidence of fetal harm. Risk cannot be excluded; use only if potential benefit justifies risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to valbenazine or any component of the formulation.","Concomitant use with monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome.","Concomitant use with strong CYP3A4 inducers (e.g., rifampin) reduces valbenazine exposure and efficacy."]
| Precautions | ["May cause somnolence and sedation; patients should not drive or operate machinery until effects are known.","Avoid use with alcohol or other CNS depressants.","QTc interval prolongation: valbenazine prolongs QTc in a dose-dependent manner; avoid use in patients with congenital long QT syndrome or with drugs known to prolong QTc.","Parkinsonism: may cause parkinsonian symptoms; use with caution in patients with Parkinson's disease.","Neuroleptic malignant syndrome (NMS): rare but potentially life-threatening."] |
Loading safety data…
| Fetal Monitoring | Monitor for infusion reactions (hypersensitivity, anaphylaxis) during administration. No specific fetal monitoring required; standard pregnancy monitoring per obstetric guidelines. |
| Fertility Effects | No human data on fertility effects. Animal studies showed no impairment of male or female fertility. |